Zobrazeno 1 - 10 of 11 pro vyhledávání: '"Gavin Ling"'
2
Inherited bleeding disorders
Autor: Pu-Lin Luo, Gavin Ling
Publikováno v: Medicine. 49:225-228
Inherited bleeding disorders (IBDs) encompass a large number of different but rare conditions that can lead to increased risk of bleeding. The most common IBDs are von Willebrand disease, haemophilia A and haemophilia B. The diagnosis of IBDs require
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::28a76eaed30473798fca2d695b1072d5
https://doi.org/10.1016/j.mpmed.2021.01.009
Zobrazit plný text záznamu
5
Factor VIII: the protein, cloning its gene, synthetic factor and now – 35 years later – gene therapy; what happened in between?
Autor: Edward G. D. Tuddenham, Gavin Ling
Publikováno v: British Journal of Haematology. 189:400-407
The foundation of haemophilia A therapy in the last 35 years has been critically dependent on isolation of the Factor VIII (FVIII) protein and discovery of the cDNA sequence of the FVIII gene, published in 1984. Identification of the FVIII sequence r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13628fb033fe15e21a1c59ff5b48aca1
https://doi.org/10.1111/bjh.16311
Zobrazit plný text záznamu
7
Prophylactic Treatment of Severe Haemophilia Á Patients with Inhibitors to FVIII with Peglip-FVIII
Autor: Gavin Ling, Edward G. D. Tuddenham, Igor Kurtov, Tatiana Pospelova, Margarita Timofeeva, Nadezhda Zozulya, Marina Kosinova
Publikováno v: Blood. 138:1040-1040
Background: FVIII replacement therapy is ineffective for severe haemophilia A (HA) patients who develop inhibitors to FVIII. Patients with intractable inhibitors currently require FVIII mimetics and/or bypassing agents to prevent bleeding. PEGylated
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::faac4fc52dcf5f5826e050773728d416
https://doi.org/10.1182/blood-2021-149533
Zobrazit plný text záznamu
8
Safety and efficacy of factor XI (FXI) concentrate use in patients with FXI deficiency: a single‐centre experience of 19 years
Autor: Gavin Ling, Pratima Chowdary, H. Kagdi, B. Subel, Keith Gomez
Publikováno v: Haemophilia. 22:411-418
Aim Factor XI (FXI) concentrate is a pooled human plasma-derived factor concentrate used as replacement therapy for patients with FXI deficiency, which provides a predictable response and consistent haemostatic cover in emergency or elective situatio
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d25385ae27ff259ff638bb25b0f28e6c
https://doi.org/10.1111/hae.12868
Zobrazit plný text záznamu
9
Real-World Clinical and Laboratory Characteristics in Severe Hemophilia a Patients Commencing Emicizumab
Autor: Gerard Dolan, Gavin Ling, Aine McCormick, Steve Austin, Aderonke Ajidahun
Publikováno v: Blood. 136:9-9
Introduction Emicizumab (a bispecific antibody mimicking Factor VIIIa) has been authorised for use in the United Kingdom National Health Service (NHS) in severe hemophilia A patients with and without inhibitors since August 2019. The Summary of Produ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::256e9add8ddaa1907953b2d899ee5f96
https://doi.org/10.1182/blood-2020-138746
Zobrazit plný text záznamu
10
Recent advances in developing specific therapies for haemophilia
Autor: Amit C. Nathwani, Edward G. D. Tuddenham, Gavin Ling
Publikováno v: British journal of haematology. 181(2)
Haemophilia therapy has undergone very rapid evolution in the last 10 years. The major limitation of current replacement therapy is the short half-life of factors VIII and IX. These half-lives have been extended by the addition of various moieties, a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::349f56165b88fb2896490baec1cd1cfe
https://pubmed.ncbi.nlm.nih.gov/29359795
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje